Markets

Dow gains 369 points on trader optimism around a COVID-19 treatment

US stocks rose on Friday as traders cheered advances in coronavirus treatment. Gilead Sciences said on Friday that an analysis of clinical-trial data for its remdesivir drug found a 62% reduction in mortality risk among severe COVID-19 patients. Still, the US on Thursday reported 63,200 new coronavirus cases, according to […]
Dow gains 369 points on trader optimism around a COVID-19 treatment
Markets

US stocks fluctuate as traders weigh virus spike against advances in treatment

US stocks fluctuated as traders weighed another record spike in virus cases against advances in treatment. On Thursday the US reported 63,200 new coronavirus cases, another record spike, according to data from Johns Hopkins University Meanwhile, Gilead Sciences released clinical-trial data on Friday suggesting its remdesivir treatment reduced COVID-19 mortality […]
US stocks fluctuate as traders weigh virus spike against advances in treatment
Markets

Gilead rises after pricing its coronavirus-fighting drug remdesivir

Gilead Sciences on Monday disclosed its pricing for remdesivir, its coronavirus-fighting drug. Shares of the company jumped as much as 4% in premarket trading. The company will charge the US government and developed countries $US390 per vial of remdesivir, or $US2,340 for a five-day course using six vials of the […]
Gilead rises after pricing its coronavirus-fighting drug remdesivir
News

The $96 billion biotech Gilead will start testing a new version of the first effective coronavirus treatment, and it could make remdesivir available to vastly more patients

The biotech giant that developed the first effective coronavirus treatment is now looking to expand its impact. Gilead Sciences CEO Daniel O’Day said Monday that the company would start testing an inhaled version of the antiviral drug remdesivir in August. Currently, the drug is given as an intravenous infusion. If […]
The $96 billion biotech Gilead will start testing a new version of the first effective coronavirus treatment, and it could make remdesivir available to vastly more patients
News

Gilead has yet to set a price for the coronavirus treatment remdesivir, but an influential drug pricing watchdog says it could be worth up to $4,500 per patient

Gilead Sciences could be justified in charging up to $US4,500 per coronavirus patient for its drug, a nonprofit pricing watchdog said in a recent report. The California biotech is the maker of remdesivir, an experimental antiviral treatment that helped hospitalized COVID-19 patients recover 31% faster, shaving four days off hospital […]
Gilead has yet to set a price for the coronavirus treatment remdesivir, but an influential drug pricing watchdog says it could be worth up to $4,500 per patient
News

Dispensed: Doctors are seeing new COVID-19 complications and symptoms, the promises and pitfalls of getting back to business, and why the healthcare industry will never be the same

Hello, Welcome to Dispensed, Business Insider’s weekly healthcare newsletter. How are you all? Can you believe we’ve been doing this for more than a month by now? This week, the healthcare team here at BI has stayed busy keeping tabs on the latest efforts to reopen parts of the country […]
Dispensed: Doctors are seeing new COVID-19 complications and symptoms, the promises and pitfalls of getting back to business, and why the healthcare industry will never be the same
Markets

One Wall Street firm says approval for Gilead’s experimental coronavirus treatment is a coin-flip bet at best — but still thinks you should buy the stock right now

Gilead’s experimental coronavirus treatment has a 50/50 chance at gaining approval at best, RBC Capital Markets analysts wrote Wednesday. The biotech company soared amid the late February downturn after a World Health Organisation official deemed its remdesivir compound the best bet yet to combat the epidemic. Though the drug’s success […]
One Wall Street firm says approval for Gilead’s experimental coronavirus treatment is a coin-flip bet at best — but still thinks you should buy the stock right now
Next Page »